Humana Inc. $HUM Shares Acquired by State Street Corp

Key Points

• State Street increased its Humana stake by 4,080 shares in the second quarter, bringing its holdings to 5.46 million shares, or approximately 4.54% of the company. Institutional investors and hedge funds collectively own 92.38% of Humana.
• Humana reported quarterly EPS of $7.61, exceeding the $7.27 consensus estimate, while revenue rose 26.2% year over year to $40.89 billion. The company also declared a quarterly dividend of $0.885 per share, representing a 1.0% annualized yield.
• Humana shares opened at $371.93, down 1.8%, while analysts maintain a consensus “Hold” rating and an average price target of $403.91.

State Street Corp lifted its stake in Humana Inc. (NYSE:HUM - Free Report) by 0.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,457,072 shares of the insurance provider's stock after purchasing an additional 4,080 shares during the period. State Street Corp owned about 4.54% of Humana worth $2,172,441,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Humana during the second quarter worth approximately $4,138,160,000. Pzena Investment Management LLC acquired a new position in Humana during the 2nd quarter worth approximately $1,749,014,000. Capital International Investors increased its position in shares of Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider's stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares during the last quarter. Norges Bank acquired a new stake in shares of Humana in the 4th quarter valued at $456,632,000. Finally, Franklin Resources Inc. lifted its position in shares of Humana by 914.5% during the 4th quarter. Franklin Resources Inc. now owns 1,255,665 shares of the insurance provider's stock worth $321,613,000 after purchasing an additional 1,131,893 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Down 1.8%

Shares of NYSE:HUM opened at $371.93 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. The company's fifty day moving average is $387.37 and its two-hundred day moving average is $314.47. Humana Inc. has a 1-year low of $163.11 and a 1-year high of $428.88. The stock has a market capitalization of $44.66 billion, a price-to-earnings ratio of 35.19, a price-to-earnings-growth ratio of 2.34 and a beta of 0.74.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.27 by $0.34. The company had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The company's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.27 earnings per share. Equities analysts anticipate that Humana Inc. will post 9 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 27th. Shareholders of record on Friday, October 30th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $3.54 annualized dividend and a yield of 1.0%. Humana's dividend payout ratio (DPR) is presently 33.49%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings upgraded Humana from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, August 14th. Mizuho increased their price target on shares of Humana from $335.00 to $390.00 and gave the stock an "outperform" rating in a report on Monday, June 8th. Wolfe Research reaffirmed an "outperform" rating and issued a $450.00 price target on shares of Humana in a report on Monday, August 24th. Robert W. Baird set a $390.00 price target on shares of Humana in a research report on Thursday, July 30th. Finally, Zacks Research downgraded Humana from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Fourteen research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Humana currently has a consensus rating of "Hold" and an average target price of $403.91.

Humana Company Profile

Humana Inc NYSE: HUM is a U.S.-based health insurance and health care services company focused primarily on government-sponsored programs. Its offerings include Medicare Advantage plans, Medicare prescription drug plans, Medicaid coverage and specialty insurance products, serving individuals, employers and government organizations.

Through its CenterWell business, Humana also provides senior-focused primary care, pharmacy services and home health care. These operations are designed to support coordinated care for older adults and other members with ongoing health care needs.

Humana was founded in 1961 as a nursing-home company and later expanded into hospital ownership before shifting its focus toward health insurance.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.